AMERICAN ORIENTAL BIOENGINEERING

As of September 30, 2013, AMERICAN ORIENTAL BIOENGINEERING has 72,987.00 shares outstanding.

As of September 30, 2013, AMERICAN ORIENTAL BIOENGINEERING maintains a current ratio of 0.51, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 32.70, indicating elevated leverage, while an interest coverage ratio of -40.64 demonstrates limited ability to service its debt obligations.

Over the twelve months ended September 30, 2013, AMERICAN ORIENTAL BIOENGINEERING posted a negative return on equity (ROE) of -28.19, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -19.60, reflecting losses generated across the asset base. The company generates approximately 32,691.93 in revenue per employee across its workforce of 3,719.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.41 indicates how many times AMERICAN ORIENTAL BIOENGINEERING sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended September 30, 2013, AMERICAN ORIENTAL BIOENGINEERING recorded 2.09M in income tax expense. The company reported a pretax loss of -88.94M and -91.02M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on August 13, 2026, AMERICAN ORIENTAL BIOENGINEERING's stock has gained approximately 2500.00% over the past 52 weeks.

Over the twelve months ended September 30, 2013, AMERICAN ORIENTAL BIOENGINEERING generated 121.58M in revenue and converted that into -91.02M in net income, yielding earnings per share of -1,248.73. EBITDA reached -65.98M, while operating income came in at -44.42M.

As of September 30, 2013, AMERICAN ORIENTAL BIOENGINEERING holds 3.23M in cash and equivalents against 92.77M in total debt, resulting in a net debt position of 89.54M. Total book value stands at 283.68M, with working capital of -61.54M providing operational flexibility.

AMERICAN ORIENTAL BIOENGINEERING produced -31.24M in operating cash flow over the twelve months ended September 30, 2013. After subtracting -24.44M in capital expenditures, free cash flow totaled -55.68M - equivalent to -763.70 per share.

Over the twelve months ended September 30, 2013, AMERICAN ORIENTAL BIOENGINEERING posted a gross margin of 32.59, reflecting its pricing power and cost economics. The operating margin of -36.53 and net profit margin of -74.86 provide insight into operational efficiency.

AMERICAN ORIENTAL BIOENGINEERING's most recent stock split took place on April 3, 2014 with a 501:1 split ratio.